Clinical Trials Browser

Active not recruiting × Lymphoma, Follicular × 30 days × Clear all

NCT03269669 2026-03-19

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT04573140 2026-03-19

PNOC020

Phase 1 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Lymphoma, Follicular

NCT02520791 2026-03-18

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Phase 1 Active not recruiting

DermatologicLymphoid

Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05627245 2026-03-18

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT03528642 2026-03-17

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Phase 1 Active not recruiting

Astrocytoma, Lymphoma, Follicular

NCT04458922 2026-03-17

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Phase 2 Active not recruiting

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT05149755 2026-03-17

Evolut™ EXPAND TAVR II Pivotal Trial

Phase NA Active not recruiting

Constriction, Pathologic, Lymphoma, Follicular

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06561425 2026-03-16

Atalanta-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05458297 2026-03-12

MK-2140-006

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT05828589 2026-03-12

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Phase 2 Active not recruiting

33 enrolled 16 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Phase 2 Active not recruiting

33 enrolled 17 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT04542824 2026-03-03

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-02-20

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin